Emtreo Injection (5gm), which contains the active ingredient Treosulfan, is a chemotherapeutic agent primarily used in the treatment of various cancers, particularly in patients undergoing stem cell transplantation. This medication is designed to help prepare the body for the transplant by conditioning the bone marrow and reducing the risk of cancer recurrence. Emtreo Injection is composed of 5 grams of Treosulfan, a prodrug that is converted into an active form in the body, exerting its effects on rapidly dividing cancer cells. The drug works by cross-linking DNA, which inhibits cell division and ultimately leads to cell death. Emtreo Injection is administered intravenously, allowing for direct delivery into the bloodstream, which enhances its efficacy in targeting cancerous tissues. This medication is crucial in oncology settings, providing a vital option for patients requiring intensive treatment regimens.